|Systematic (IUPAC) name|
|(2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide|
|Legal status||POM (UK)|
|Mol. mass||233.243 g/mol|
| (what is this?)
Sulbactam is a beta-lactamase inhibitor. This molecule is given in combination with beta-lactam antibiotics to inhibit beta-lactamase, an enzyme produced by bacteria that destroys the antibiotics. 
Sulbactam is an irreversible inhibitor of beta-lactamase; it binds the enzyme and does not allow it to interact with the antibiotic.
Sulbactam is able to inhibit the most common forms of beta-lactamase but is not able to interact with the ampC cephalosporinase. Thus, it confers little protection against bacteria such as Pseudomonas aeruginosa, Citrobacter, Enterobacter, and Serratia, which often express this gene.
In the United States, sulbactam is combined to form cefoperazone/sulbactam and ampicillin/sulbactam. It does possess some antibacterial activity when administered alone, but it is too weak to have any clinical importance. Its use in the UK is restricted to hospitals.
Recently its use in treating Acinetebacter septicemia is receiving renewed interest,
See also 
- Totir MA, Helfand MS, Carey MP, et al. (August 2007). "Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase". Biochemistry 46 (31): 8980–7. doi:10.1021/bi7006146. PMC 2596720. PMID 17630699.
- Singh GS (January 2004). "Beta-lactams in the new millennium. Part-II: cephems, oxacephems, penams and sulbactam". Mini Rev Med Chem 4 (1): 93–109. doi:10.2174/1389557043487547. PMID 14754446.
|This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.|